Cart
sales@molnova.com
TAK-931
CAS No. 1330782-76-7
TAK-931 ( Simurosertib;TAK931 )
Catalog No. M11316 CAS No. 1330782-76-7
TAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 87 | Get Quote |
|
| 5MG | 170 | Get Quote |
|
| 10MG | 237 | Get Quote |
|
| 25MG | 440 | Get Quote |
|
| 50MG | 642 | Get Quote |
|
| 100MG | 888 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTAK-931
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM.
-
DescriptionTAK-931 (Simurosertib) is a potent, selective, ATP competitive and orally bioavailable inhibitor of Cdc7 with IC50 of <0.3 nM; prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis, demonstrates antiproliferative activity with cancer cell lines and tumor growth inhibition (TGI) in murine ectopic xenograft models. Colon Cancer,Phase 2 Clinical
-
SynonymsSimurosertib;TAK931
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationColon Cancer
Chemical Information
-
CAS Number1330782-76-7
-
Formula Weight341.43
-
Molecular FormulaC17H19N5OS
-
Purity>98% (HPLC)
-
SolubilityDMSO : 75 mg/mL 219.66 mM
-
SMILESO=C1C2=C(C=C(C3=CNN=C3C)S2)N=C([C@H]4N(CC5)CCC5C4)N1
-
Chemical NameThieno[3,2-d]pyrimidin-4(3H)-one, 2-(2S)-1-azabicyclo[2.2.2]oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Charles Locuson, et al. Abstract 5041: Translational pharmacokinetic-pharmacodynamic xenograft model for TAK-931, a small molecule cell division cycle 7 (CDC7) kinase inhibitor. AACR.
2. Kenichi Iwai, et al. Abstract 3073: Potential predictive biomarkers of clinical responses for a novel CDC7-selective inhibitor TAK-931. AACR.
2. Kenichi Iwai, et al. Abstract 3073: Potential predictive biomarkers of clinical responses for a novel CDC7-selective inhibitor TAK-931. AACR.
molnova catalog
related products
-
HSD992
HSD992 is a potent, selective CDK2/3 inhibitor with moderate CDK9 inhibition with IC50 of 18 nM, 57 nM and 49 nM for CDK3/cyclin E, CDK2/cyclin A1 and CDK2/cyclin E, respecively.
-
JSH-150
JSH-150 (JSH150) is a potent, highly selective inhibitor of CDK9 kinase with IC50 of 1 nM in the biochemical assays, displays 300-10000-fold selectivity over other CDK kinase family members (CDK7 IC50=1.72 uM).
-
Bohemine
Bohemine is a cyclin-dependent kinase inhibitor.
